Eculizumab biosimilar (Biocad)

依库丽单抗生物类似药 (Biocad)

Report date: 2023/04/14 20:00:48

Base Information

Drug NameEculizumab biosimilar (Biocad)

Drug Alias Name依库丽单抗生物仿制药 (Biocad)BCD-148

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionComplement C5 inhibitors

TargetsComplement C5

Therapy Area/IndicationsHemoglobinuria, Paroxysmal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesBIOCAD JSC

China Registration ClassN/A

Active CompaniesBIOCAD JSC

Inactive CompaniesN/A

Active IndicationsHemoglobinuria, Paroxysmal

Inactive IndicationsN/A

ATC CodeL04AJ01